Live news related to CELLECTIS stock (FR0010425595): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on CELLECTIS mainly cover M&A activity, share price moves et earnings publications. The stock trades at €2,59 on Euronext Paris, up 5,28% at the last update. This page lists the articles published on CELLECTIS stock to track the share price, company announcements and any item likely to influence market perception.
Cellectis presented on Thursday the final Phase 1 results for lasmé-cel and preliminary data for éti-cel at the EHA 2026 congress. Both allogeneic CAR…
The French biotech company experienced a significant rebound session following the announcement of a major U.S. regulatory designation for its allogen…
The U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to lasmé-cel, an allogeneic CAR-T candidate from Cellectis targeting the…
Cellectis announced on Tuesday the presentation of clinical data on two allogeneic CAR-T candidates at the annual congress of the European Hematology …
Cellectis announced its financial results for the first quarter of 2026 on Monday, reporting a nearly stable net loss of $17.8 million, but with an in…
Cellectis introduces new research on an epigenetic editing approach based on TALE at the annual conference of the American Society of Gene and Cell Th…
Cellectis reveals new research on a TALE-based epigenetic editing technology that modifies gene expression without altering the DNA sequence, at the a…
Cellectis' flagship program records an intermediate clinical success. The futility analysis of the pivotal ALPHA3 trial, conducted by its partner Allo…
Allogene Therapeutics has announced the results of an interim futility analysis of the ALPHA3 pivotal trial evaluating cema-cel, a candidate product d…
The biotech company's stock is among the few showing significant gains this Monday, while the CAC 40 drops by 0.87% during the session. Cellectis has …
